SCHEMBL9821986

SCHEMBL9821986

C=CCN(CC=C)c1nc(Cl)nc(Cl)n1

nearest known ligand 0.37

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 4/20 0.37
ALDH1A1 P00352 2/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9821919 0.95 CRHR1 (0.37) CRHR1ALDH1A1ALOX15TSHR
SCHEMBL29152865 0.86 PDE4A (0.35) CRHR1
SCHEMBL208774 0.83 CRHR1 (0.42) CRHR1TSHRTDP1
SCHEMBL11666361 0.82 ALDH1A1 (0.36) ALDH1A1ALOX15TSHRTDP1
SCHEMBL10522088 0.82 ALDH1A1 (0.36) CRHR1ALDH1A1
SCHEMBL11079340 0.78 ALDH1A1 (0.35) ALDH1A1ALOX15TSHRTDP1
SCHEMBL7428851 0.78 CRHR1 (0.42) CRHR1
SCHEMBL4856417 0.78 CRHR1 (0.33) CRHR1ALDH1A1
SCHEMBL7937496 0.74 CRHR1 (0.31) CRHR1
SCHEMBL10522528 0.74 CRHR1 (0.37) CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4016013-A OR CARBONITRIDESDECOMPOSITION OF TRIAZINE OR PYRIMIDINE COMPOUNDS CIBA-GEIGY CORPORATION (US) 1977-04-05 US claimed
JP-60098621-A None JP disclosed
JP-60097352-A None JP disclosed
US-8987383-B2 Triazine derivatives and application thereof NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) 2015-03-24 US disclosed
US-20130023629-A1 TRIAZINE DERIVATIVES AND APPLICATION THEREOF SHINRYO CORPORATION (JP) 2013-01-24 US disclosed
EP-2537833-A1 TRIAZINE DERIVATIVE, AND APPLICATION THEREOF Nippon Kasei Chemical Company Limited (JP) 2012-12-26 EP disclosed
EP-0129036-B1 POLYAMIDE-POLYOL BLOCK COPOLYMERS AND ANIONIC POLYMERIZATION PROCESS AlliedSignal Inc. (US) 1991-12-18 EP disclosed
EP-0373892-A1 Tetramethyl piperidyl terminated triazine oligomeric esters and amides ICI AMERICAS INC. (US) 1990-06-20 EP disclosed
US-4889882-A RADIATION RESISTANCE, PHOTOSTABILITY POLYMER ADDITIVE ICI AMERICAS INC. (US) 1989-12-26 US disclosed
EP-0082244-B1 NOVEL LIGHT STABILIZERS FOR POLYMERS AMERICAN CYANAMID COMPANY (US) 1986-03-19 EP disclosed
US-4540728-A Diallyl-1,3,5-triazino-4-(2,2,6,6-tetramethyl piperidyl) amines as monomers and polymers and stabilized synthetic resin compositions ADEKA ARGUS CHEMICAL CO., LTD. (JP) 1985-09-10 US disclosed
JP-S6098621-A RINSING LIQUID FOR NEGATIVE TYPE ELECTRON-RAY RESIST KANTO KAGAKU KK 1985-06-01 JP disclosed
JP-S6097352-A DEVELOPER FOR NEGATIVE TYPE ELECTRON BEAM RESIST KANTO KAGAKU KK 1985-05-31 JP disclosed
EP-0129036-A2 Polyamide-polyol block copolymers and anionic polymerization process AlliedSignal Inc. (US) 1984-12-27 EP disclosed
US-4487920-A POLYLACTAM-POLYETHER COPOLYMERS; REATION INJECTION MOLDING; IMPACT STRENGTH ALLIED CORPORATION (US) 1984-12-11 US disclosed
EP-0082244-A1 Novel light stabilizers for polymers AMERICAN CYANAMID COMPANY (US) 1983-06-29 EP disclosed
US-4054559-A Reactive disazo monohalogenotriazine dyestuffs NIPPON KAYAKU KABUSHIKI KAISHA (JA) 1977-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023629-A1 TRIAZINE DERIVATIVES AND APPLICATION THEREOF HSPH1, PRDX3, PRXL2A CRHR1 658/4885ALDH1A1 299/4885ALOX15 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.